Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11863728 | 0.87 | P2RX7 (0.45) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL1053969 | 0.82 | TSHR (0.55) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL8036242 | 0.81 | ADRA2A (0.46) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL30647211 | 0.80 | ESR1 (0.52) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL624799 | 0.80 | ESR1 (0.52) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL16308863 | 0.80 | ESR1 (0.52) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL29403593 | 0.80 | ESR1 (0.52) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL196657 | 0.80 | TSHR (0.50) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL16308826 | 0.80 | ESR1 (0.52) | TSHRADRA2AADRA2BADRA2CCYP1A2 | |
| SCHEMBL11859274 | 0.79 | P2RX7 (0.40) | TSHRADRA2AADRA2BADRA2CCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3962357-A | FROM SUBSTITUTED ETHYLTOLUENE, CONTINUOUS, SINGLE STEP | ROHM AND HAAS COMPANY (US) | 1976-06-08 | — | — | US | claimed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| CN-106866538-B | A kind of preparation method of Dexmedetomidine and its intermediate | 江苏恒瑞医药股份有限公司 | 2019-04-05 | — | — | CN | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
| CN-106588780-A | Process for preparing dexmedetomidine hydrochloride intermediate | 青岛辰达生物科技有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106187901-A | Preparation method of dexmedetomidine and intermediate thereof | 江苏恒瑞医药股份有限公司 | 2016-12-07 | — | — | CN | disclosed |
| US-3962357-A | FROM SUBSTITUTED ETHYLTOLUENE, CONTINUOUS, SINGLE STEP | ROHM AND HAAS COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TSHR 840/4885ADRA2A 3218/4885ADRA2B 2991/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TSHR 840/4885ADRA2A 3218/4885ADRA2B 2991/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TSHR 840/4885ADRA2A 3218/4885ADRA2B 2991/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | TSHR 284/4885ADRA2A 2938/4885ADRA2B 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.